Seres Therapeutics (MCRB) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/03/21
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business UpdatesBusiness Wire • 08/03/21
Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021Business Wire • 07/29/21
Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative ColitisBusiness Wire • 07/22/21
Seres Therapeutics Stock Plunges As Ulcerative Colitis Candidate Disappoints In Mid-Stage StudyBenzinga • 07/22/21
Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative ColitisBusiness Wire • 07/22/21
Implied Volatility Surging for Seres Therapeutics (MCRB) Stock OptionsZacks Investment Research • 07/07/21
Forensic Value Stock Selections: Top Positive And Negative Scoring Stocks For Mid-Year 2021Seeking Alpha • 07/06/21
Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License AgreementBusiness Wire • 07/01/21
Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingBusiness Wire • 06/04/21
Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)Business Wire • 06/01/21
Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021Business Wire • 05/21/21
Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business DevelopmentBusiness Wire • 05/20/21
Seres Therapeutics to Present Clinical Research on the Microbiome's Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingBusiness Wire • 05/19/21
Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare ConferenceBusiness Wire • 05/12/21
Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual MeetingBusiness Wire • 05/11/21
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/04/21